Low expression of insulin-like growth factor binding protein 7 associated with poor prognosis in human glioma

Tian, Xiangyang; Zhang, Ling; Sun, Laiguang; Xue, Yihong; Xie, Shuang

doi:10.1177/0300060513503926

Cited by 9 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, according to our results and consistent with the research conclusions reported, TMEM149 and EVI2B are required further study with corresponding tumor types to find better prognostic biomarkers. In addition, we found 74 other immune-related genes with a significant prognostic role for at least one tumor type, some of which have been reported by previous studies ( 49 – 52 ). Overall, these results suggest new possibilities for immune-related prognostic biomarkers, but further experimental and functional studies urgently need to be carried out to validate their predictive roles.…”

Section: Discussionsupporting

confidence: 81%

Identification of Immune-Related Prognostic Biomarkers Based on the Tumor Microenvironment in 20 Malignant Tumor Types With Poor Prognosis

et al. 2020

View full text Add to dashboard Cite

Cancer, especially malignant tumors with poor prognosis, has become a major hazard to human life and health. The tumor microenvironment is gaining increasing attention from researchers, as it offers a new focus for tumor diagnosis, therapy, and prognosis. The numbers of immune and stromal cells, which are major components of the tumor microenvironment, could be determined from RNA-seq data with the Estimation of STromal and Immune cells in Malignant Tumors using Expression data (ESTIMATE) algorithm. To explore the effects of immune and stromal cells on tumor prognosis, we analyzed associations between overall survival and immune/stromal scores for 20 malignant tumor types based on The Cancer Genome Atlas (TCGA) data. For six of the 20 tumor types, we observed statistically significant associations. Furthermore, to better explain the predictive ability of these scores, differentially expressed genes (DEGs) were identified in groups of cases with high or low immune or stromal scores for each of these six malignant tumor types. In addition, a list of immune-related genes was screened to identify prognostic predictors for one or more tumor types. Thus, multi-database joint analysis can provide a new approach to the assessment of tumor prognosis and allow the identification of related genes that may be new biomarkers for tumor metastasis and prognosis.

show abstract

Section: Discussionsupporting

confidence: 81%

Identification of Immune-Related Prognostic Biomarkers Based on the Tumor Microenvironment in 20 Malignant Tumor Types With Poor Prognosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It regulates some genes (including insulin-like growth factor 2, -actin and-transduction proteins) translation by binding to their mRNA. Some studies [55,56] found that IGFBP subtype has become a biomarker for diagnosis and prognosis of astrocytomas. IGF2BP3 was identified as a GBM-specific proliferative and pre-invasive marker that activates the oncogene PI3K and MAPK pathways through the action of IGF-2 [57].…”

Section: Discussionmentioning

confidence: 99%

Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma

et al. 2019

View full text Add to dashboard Cite

Background The aim of this study was to identify gene signals for lower-grade glioma (LGG) and to assess their potential as recurrence biomarkers. Material/Methods An LGG-related mRNA sequencing dataset was downloaded from The Cancer Genome Atlas (TCGA) Informix. Multiple bioinformatics analysis methods were used to identify key genes and potential molecular mechanisms in recurrence of LGG. Results A total of 326 differentially-expressed genes (DEGs), were identified from 511 primary LGG tumor and 18 recurrent samples. Gene ontology (GO) analysis revealed that the DEGs were implicated in cell differentiation, neuron differentiation, negative regulation of neuron differentiation, and cell proliferation in the forebrain. The Kyoto Encyclopedia of Genes and Genomes (KEGG) database suggests that DEGs are associated with proteoglycans in cancer, the Wnt signaling pathway, ECM-receptor interaction, the PI3K-Akt signaling pathway, transcriptional deregulation in cancer, and the Hippo signaling pathway. The hub DEGs in the protein–protein interaction network are apolipoprotein A2 (APOA2), collagen type III alpha 1 chain (COL3A1), collagen type I alpha 1 chain (COL1A1), tyrosinase (TYR), collagen type I alpha 2 chain (COL1A2), neurotensin (NTS), collagen type V alpha 1 chain (COL5A1), poly(A) polymerase beta (PAPOLB), insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), and anomalous homeobox (ANHX). GSEA revealed that the following biological processes may associated with LGG recurrence: cell cycle, DNA replication and repair, regulation of apoptosis, neuronal differentiation, and Wnt signaling pathway. Conclusions Our study demonstrated that hub DEGs may assist in the molecular understanding of LGG recurrence. These findings still need further molecular studies to identify the assignment of DEGs in LGG.

show abstract

“…Tian et al found that IGFBP7 mRNA levels were substantially decreased in human glioma in comparison to healthy brain tissue (110) and that low levels of IGFBP7 mRNA were associated with larger tumor size, and patients with higher IGFBP7 expression had longer overall survival. Pen et al (111) described that IGFBP7 acts as a tumor suppressor by lowering glioblastoma cell growth and inducing senescence, although not programmed cell death (111).…”

Section: Igfbp7 With Mesenchymal Tumors Gliomamentioning

confidence: 99%

Insulin Growth Factor Binding Protein 7 (IGFBP7)-Related Cancer and IGFBP3 and IGFBP7 Crosstalk

Shen

Weinfeld

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

The insulin/insulin-like growth factors (IGFs) have crucial tasks in the growth, differentiation, and proliferation of healthy and pernicious cells. They are involved in coordinated complexes, including receptors, ligands, binding proteins, and proteases. However, the systems can become dysregulated in tumorigenesis. Insulin-like growth factor-binding protein 7 (IGFBP7) is a protein belonging to the IGFBP superfamily (also termed GFBP-related proteins). Numerous studies have provided evidence that IGFBP3 and IGFBP7 are involved in a variety of cancers, including hepatocellular carcinoma (HCC), breast cancer, gastroesophageal cancer, colon cancer, prostate cancer, among many others. Still, very few suggest an interaction between these two molecules. In studying several cancer types in our laboratories, we found that both proteins share some crucial signaling pathways. The objective of this review is to present a comprehensive overview of the relationship between IGFBP7 and cancer, as well as highlighting IGFBP3 crosstalk with IGFBP7 reported in recent studies.

show abstract

Low expression of insulin-like growth factor binding protein 7 associated with poor prognosis in human glioma

Cited by 9 publications

References 32 publications

Identification of Immune-Related Prognostic Biomarkers Based on the Tumor Microenvironment in 20 Malignant Tumor Types With Poor Prognosis

Identification of Immune-Related Prognostic Biomarkers Based on the Tumor Microenvironment in 20 Malignant Tumor Types With Poor Prognosis

Use of Genome-Scale Integrated Analysis to Identify Key Genes and Potential Molecular Mechanisms in Recurrence of Lower-Grade Brain Glioma

Insulin Growth Factor Binding Protein 7 (IGFBP7)-Related Cancer and IGFBP3 and IGFBP7 Crosstalk

Contact Info

Product

Resources

About